Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1845-1853

  Straume, Oddbjørn ^a   Sviland, Lisbet ^a   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GROWTH CURVE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

AGED; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034103810     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Kamb, A., Gruis, N. A., Weaver Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
2. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
3. Liggett, W. H., Jr., and Sidransky, D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol., 16: 1197-1206, 1998.
4. Bartkova, J., Lukas, J., Guldberg, P., Alsner, J., Kirkin, A. F., Zeuthen, J., and Bartek, J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res., 56: 5475-5483, 1996.
5. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bora, S. G., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
6. Pollock, P. M., Yu, F., Qiu, L., Parsons, P. G., and Hayward, N. K. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11: 663-668, 1995.
7. Platz, A., Ringborg, U., Lagerlof, B., Lundqvist, E., Sevigny, P., and Inganas, M. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br. J. Cancer, 73: 344-348, 1996.
8. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res., 56: 5023-5032, 1996.
9. INK4a) gene in microdissected sporadic primary melanomas. Int. J. Cancer, 75: 193-198, 1998.
10. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
11. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
12. Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Frye, C., Eeles, R., Orlow, I., Lacombe, L., Ponce-Castaneda, V., Lianes, P., Latres, E., Skolnick, M., Cordon-Cardo, C., and Kamb, A. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol., 146: 1199-1206, 1995.
13. INK4 in sporadic melanoma. J. Investig. Dermatol., 107: 318-321, 1996.
14. Reed, J. A., Loganzo, F., Jr., Shea, C. R., Walker, G. J., Flores, J. F., Glendening, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., Fountain, J. W., and Albino, A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55: 2713-2718, 1995.
15. INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int. J. Cancer, 74: 255-259, 1997.
16. INK4 in benign and malignant melanocytic lesions. J. Investig. Dermatol., 110: 932-938, 1998.
17. INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J. Cutan. Pathol., 25: 291-296, 1998.
18. WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am. J. Dermatopathol., 20: 255-261, 1998.
19. Straume, O., and Akslen, L. A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int. J. Cancer, 74: 535-539, 1997.
20. Bartsch, D., Shevlin, D. W., Callery, M. P., Norton, J. A., Wells, S. A., Jr., and Goodfellow, P. J. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J. Natl. Cancer Inst., 88: 680-682, 1996.
21. Hu, Y. X., Watanabe, H., Ohtsubo, K., Yamaguchi, Y., Ha, A., Okai, T., and Sawabu, N. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin. Cancer Res., 3: 1473-1477, 1997.
22. Takeuchi, H., Ozawa, S., Ando, N., Shih, C. H., Koyanagi, K., Ueda, M., and Kitajima, M. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin. Cancer Res., 3: 2229-2236, 1997.
23. Yamada, Y., Hatta, Y., Murata, K., Sugawara, K., Ikeda, S., Mine, M., Maeda, T., Hirakata, Y., Kamihira, S., Tsukasaki, K., Ogawa, S., Hirai, H., Koeffler, H. P., and Tomonaga, M. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J. Clin. Oncol., 15: 1778-1785, 1997.
24. Kawabuchi, B., Moriyama, S., Hironaka, M., Fujii, T., Koike, M., Moriyama, H., Nishimura, Y., Mizuno, S., and Fukayama, M. p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. Int. J. Cancer, 84: 49-53, 1999.
25. Elder, D. E., and Murphy, G. F. Melanocytic tumors of the skin. In: J. Rosai and L. H. Sobin (eds.), Atlas of Tumor Pathology, pp. 119-131. Washington DC: Armed Forces Institute of Pathology, 1991.
26. Straume, O., and Akslen, L. A. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer (Phila.), 78: 1211-1219, 1996.
27. Breslow, A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg., 172: 902-908, 1970.
28. Clark, W. J., From, L., and Bernardino, E. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res., 29: 705-727, 1969.
29. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
30. Salvesen, H. B., and Akslen, L. A. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer, 84: 538-543, 1999.
31. Weidner, N., Moore, D. H., II, and Vartanian, R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum. Pathol., 25: 337-342, 1994.
32. Norusis, M. SPSS Advanced Statistics 6.1. Cary, NC: SPSS Inc., 1994.
33. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc., 34: 187-222, 1972.
34. Emig, R., Magener, A., Ehemann, V., Meyer, A., Stilgenbauer, F., Volkmann, M., Wallwiener, D., and Sinn, H. P. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br. J. Cancer, 78: 1661-1668, 1998.
35. Morita, R., Fujimoto, A., Hatta, N., Takehara, K., and Takata, M. Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J. Investig. Dermatol., 111: 919-924, 1998.
36. Healy, E., Rehman, I., Angus, B., and Rees, J. L. Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes Cancer, 12: 152-156, 1995.
37. Ohta, M., Berd, D., Shimizu, M., Nagai, H., Cotticelli, M. G., Mastrangelo, M., Shields, J. A., Shields, C. L., Croce, C. M., and Huebner, K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int. J. Cancer, 65: 762-767, 1996.
38. Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver Feldhaus, J., Gruis, N. A., Eddington, K., Allalunis Turner, M. J., Skolnick, M. H., Fujimura, F. K., and Kamb, A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10: 1061-1067, 1995.
39. Piccinin, S., Doglioni, C., Maestro, R., Vukosavljevic, T., Gasparotto, D., D'Orazi, C., and Boiocchi, M. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int. J. Cancer, 74: 26-30, 1997.
40. Gonzalgo, M. L., Bender, C. M., You, E. H., Glendening, J. M., Flores, J. F., Walker, G. J., Hayward, N. K., Jones, P. A., and Fountain, J. W. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res., 57: 5336-5347, 1997.
41. INK4a expression in resected non-small cell lung tumors. Cancer Res., 56: 3415-3420, 1996.
42. Ramsay, J. A., From, L., Iscoe, N. A., and Kahn, H. J. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J. Investig. Dermatol., 105: 22-26, 1995.
43. Vogt, T., Zipperer, K. H., Vogt, A., Holzel, D., Landthaler, M., and Stolz, W. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology, 30: 57-63, 1997.
44. Stretch, J. R., Gatter, K. C., Ralfkiaer, E., Lane, D. P., and Harris, A. L. Expression of mutant p53 in melanoma. Cancer Res., 51: 5976-5979, 1991.
45. Akslen, L. A., and Morkve, O. Expression of p53 protein in cutaneous melanoma. Int. J. Cancer, 52: 13-16, 1992.
46. Albino, A. P., Vidal, M. J., McNutt, N. S., Shea, C. R., Prieto, V. G., Nanus, D. M., Palmer, J. M., and Hayward, N. K. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res., 4: 35-45, 1994.
47. Akslen, L. A., Monstad, S. E., Larsen, B., Straume, O., and Ogreid, D. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int. J. Cancer, 79: 91-95, 1998.
48. Korabiowska, M., Brinck, U., Hoenig, J. F., Bartkowski, S. B., Kellner, S., Marx, D., and Schauer, A. Significance of P-53 antigen in malignant melanomas and naevi of the head and neck area. Anticancer Res., 15: 885-889, 1995.
49. Karjalainen, J. M., Eskelinen, M. J., Kellokoski, J. K., Reinikainen, M., Alhava, E. M., and Kosma, V. M. p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br. J. Cancer, 79: 895-902, 1999.
50. Hall, P. A., and Lane, D. P. p53 in tumor pathology: can we trust immunohistochemistry? - Revisited. J. Pathol., 172: 1-4, 1994.
51. Schuchter, L., Schultz, D. J., Synnestvedt, M., Trock, B. J., Guerry, D., Elder, D. E., Elenitsas, R., Clark, W. H., and Halpern, A. C. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann. Intern. Med., 125: 369-375, 1996.